Denosumab in osteoarthritis: from mechanism to clinical translation - Takeaways - MDSpire

Denosumab in osteoarthritis: from mechanism to clinical translation

  • By

  • Jiaoniu Duan

  • Gailian Zhang

  • Liyun Zhang

  • May 25, 2026

  • 0 min

Share

  • 1

    Osteoarthritis affects over 600 million people globally, yet no disease-modifying drugs have been approved to alter its progression.

  • 2

    Denosumab, a monoclonal antibody targeting RANKL, shows promise as a potential disease-modifying osteoarthritis drug based on preclinical and clinical evidence.

  • 3

    Denosumab disrupts inflammatory pathways in osteoarthritis by blocking RANKL signaling, which reduces pro-inflammatory mediators and macrophage activation.

  • 4

    A phase 2a trial demonstrated that denosumab significantly improved joint function and reduced erosive joint progression in patients with erosive hand osteoarthritis.

  • 5

    Long-term safety and efficacy of denosumab in non-osteoporotic osteoarthritis patients require further investigation through larger multicenter studies.

Original Source(s)

Denosumab in osteoarthritis: from mechanism to clinical translation

  • by Jiaoniu Duan, Gailian Zhang, Liyun Zhang

  • May 25, 2026

Related Content

Exercise in Osteoarthritis: Does It Help?

Overview data on exercise therapy in osteoarthritis question its universal promotion

Robotic Hip Arthroplasty May Improve Precision

Systematic review found robotic-assisted total hip arthroplasty improved implant positioning precision without demonstrating better patient-reported outcomes or lower complication rates than conventional surgery.

May Ultraprocessed Foods Raise Muscle Fat?

MRI study suggests higher intake is associated with greater intramuscular fat in patients at risk for knee osteoarthritis.